REGULATORY

Veklury Expands Label for Mild COVID-19

March 22, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Gilead Sciences’ antiviral Veklury (remdesivir) is now officially allowed for use in mild COVID-19 with its label expanded to patients with risks factors for progression to severe disease. The Pharmaceuticals and Medical Devices Agency (PMDA) announced the update on March…

To read the full story

Veklury Use in Mild COVID-19 Could Be Considered: MHLW
January 31, 2022
PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021

REGULATORY

Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
Lower House Clears Immunization Act Revision
July 1, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…